Bristol Myers Squibb Announces Five-Year Survival Outcomes for Opdivo in Previously Treated Advanced NSCLC

Bristol-Myers Squibb Company (NYSE ticker symbol:BMY) announced todayCheckMate -017andCheckMate -057For previously treated advanced non-small cell lung cancer (NSCLC) Patient's clinical3Long-term pooled efficacy and safety results. After five years of treatment, usingOpdivo（nivolumab) compared with patients administered docetaxel, the long-term overall survival rate (OS) increase. OpdivoFive-YearOSrate is13.4%, docetaxel is2.6%. In comparisons across all subgroups, it was observed thatOpdivoImproved the treatment of patientsOSRate.

OpdivoSafety during the course of treatment compared to previously reported second-lineNSCLCThe results were consistent, with no new safety signals identified during extended follow-up. Among patients still under investigation,70Among the patients, only2Name at the top3Year and No.4new treatment-related selections between yearsAE, and while still under research55Among the named patients, in the4Year and No.5No reports requiring selection of new treatment-related items were filed between the years.AE。

In theOpdivoAmong patients with an objective response,32.2% of patients at5Continued response within the year. Among patients who had an objective response to docetaxel,0% in5Still responsive in old age. OpdivoThe median duration of response in treated patients was19.9months, the duration of response in patients treated with docetaxel was5.6months.

Yale Cancer Center MedicineTumorProfessor Scott Gettinger commented, “The cumulative five-yearCheckMate -017and057The data highlight this patient populationOpdivo“Durable Efficacy Compared with Traditional Chemotherapy.”

Head of Development, Thoracic Cancer Division, Bristol-Myers SquibbSabine MaierThe doctor said, “Patients who have undergone standardized chemotherapy have never had a five-year survival rate lower than5%. Self2015U.S. Food and Drug Administration ApprovalOpdivoSince the introduction of second-line treatment for non-small cell lung cancer,Opdivohas become an important treatment option for patients who have undergone standard chemotherapy. The long-term survival outcomes in large patient populations from these two studies confirm thatOpdivodurability of the treatment regimen.Opdivoof durability has now been demonstrated in variousTumorconfirmed in the types and treatment methods.

This pooled analysis was conducted in the clinical3Phase randomized trial receiving immunotherapyTumorTherapeuticNSCLCThe Longest Follow-up Study of Patients, Today (09Month10day) at noon Central European Summer Time12：00-12：10The International Association for the Study of Lung Cancer held in Barcelona, Spain (IASLC) Article20World Conference on Lung Cancer (WCLC) deliver an oral presentation. (BioValleyBioon.com)

Original Source:Bristol-Myers Squibb Official Website